Healthcare Finance News June 14, 2024
The trials will evaluate novel vaccines administered as a nasal spray or as a pill to protect against symptomatic COVID-19.
The Biomedical Advanced Research and Development Authority (BARDA) is setting aside up to $500 million in Project NextGen funding to plan and execute multiple Phase 2b clinical trials evaluating novel vaccines administered as a nasal spray or as a pill to protect against symptomatic COVID-19.
BARDA is part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services.
“We learned a lot during the COVID-19 pandemic that we can use to better prepare for future public health crises,” said HHS Secretary Xavier Becerra. “That includes finding new ways to administer vaccines to...
Today's Sponsors
Today's Sponsor